Neoadjuvant Sacituzumab Govitecan Displays Activity in Muscle-Invasive Bladder Cancer, But Questions Remain

Neoadjuvant sacituzumab govitecan demonstrated efficacy in patients with muscle-invasive bladder cancer, but its future role in the space is uncertain.

Related Keywords

Italy ,Milan ,Lombardia ,Thomas Powles ,Antonio Cigliola ,Oncology Department ,Barts Cancer Centre At St ,Medical Oncology Department ,Raffaele Hospital ,Genitourinary Oncology ,Barts Cancer Centre ,